245107-73-7

Basic information

• Synonyms: Butanamide, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-N-methoxy-N-methyl-, (3R)-
• CAS NO: 245107-73-7
• Molecular Formula: C₁₂H₂₇NO₃Si
• Molecular Weight: 261.43
• Mol File: 245107-73-7.mol

Chemical Properties

• Boiling Point: 269.3±42.0 °C(Predicted)
• Appearance: /
• Density: 0.934±0.06 g/cm3(Predicted)
• CAS DataBase Reference: N/A(CAS DataBase Reference)
• NIST Chemistry Reference: N/A(245107-73-7)
• EPA Substance Registry System: N/A(245107-73-7)

Safety Data

• Hazardous Substances Data: 245107-73-7(Hazardous Substances Data)

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 104524-19-8 methyl (R)-(-)-3-(tert-butyldimethylsilyloxy)butyrate 
• 105729-41-7 3-(R)-t-butyldimethylsilyloxybutanoic acid 
• 1608495-05-1 C₁₁H₁₅NO₅ 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 109715-46-0 ethyl (R)-3-[(tert-butyldimethylsilyl)oxy]butanoate 
• 379669-02-0 (3R)-3-hydroxy-N-methoxy-N-methylbutyramide 

Downstream Products

• 913986-18-2 C₂₃H₃₇NO₄Si 

Relevant articles and documents

Mechanistic insight with HBCH2CoA as a probe to polyhydroxybutyrate (PHB) synthases

Polyhydroxybutyrate (PHB) synthases catalyze the polymerization of 3-(R)-hydroxybutyrate coenzyme A (HBCoA) to produce polyoxoesters of 1-2 MDa. A substrate analogue HBCH2CoA, in which the S in HBCoA is replaced with a CH2 group, was synthesized in 13 steps using a chemoenzymatic approach in a 7.5% overall yield. Kinetic studies reveal it is a competitive inhibitor of a class I and a class III PHB synthases, with Kis of 40 and 14 μM, respectively. To probe the elongation steps of the polymerization, HBCH2CoA was incubated with a synthase acylated with a [ 3H]-saturated trimer-CoA ([3H]-sTCoA). The products of the reaction were shown to be the methylene analogue of [3H]-sTCoA ([3H]-sT-CH2-CoA), saturated dimer-([3H]-sD- CO2H), and trimer-acid ([3H]-sT-CO2H), distinct from the expected methylene analogue of [3H]-saturated tetramer-CoA ([3H]-sTet-CH2-CoA). Detection of [3H]-sT- CH2-CoA and its slow rate of formation suggest that HBCH 2CoA may be reporting on the termination and repriming process of the synthases, rather than elongation.

Synthesis and biological testings as inhibitors of HMGCoA reductase of the seco-acid of tuckolide and its C-7 epimer

The seco-acid of the natural macrolactone, tuckolide (decarestrictin D) and the C-7 epimer have been prepared in enantiomerically pure form from d-gluconolactone and poly(3-hydroxy butyric acid). The key steps are Horner-Emmons olefination and stereoselective reduction of the resulting enone to provide both epimers at C-7. None of the seco-acids inhibit microsomal HMGCoA reductase of pea or rat liver. It may be concluded that the cholesterol biosynthesis inhibiting effect of tuckolide is unlikely to proceed via HMGCoA reductase inhibition. Copyright (C) 1999 Elsevier Science Ltd.

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of formula I, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in th

A highly efficient synthesis of (-)-pinidinol

A short step synthesis of the bioactive piperidine alkaloid (-)-pinidinol was achieved using a cross metathesis and a reductive amination as the key steps.